Theriva Biologics SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic AdenocarcinomaMetastatic
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Theriva Biologics SL
- Target Recruit Count
- 112
- Registration Number
- NCT05673811
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of California - Davis Cancer Center, Sacramento, California, United States
🇺🇸University of Louisville - Brown Cancer Center, Louisville, Kentucky, United States
A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Theriva Biologics SL
- Target Recruit Count
- 8
- Registration Number
- NCT02045589
- Locations
- 🇪🇸
Institut Català d'Oncologia, L'Hospitalet De Llobregat, Barcelona, Spain
🇪🇸Centro Integral Oncológico Clara Campal, Madrid, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Pancreatic AdenocarcinomaLocally Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Theriva Biologics SL
- Target Recruit Count
- 42
- Registration Number
- NCT02045602
- Locations
- 🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Centro Integral Oncológico Clara Campal, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath